Paper · 42955441
SLC2A1 promotes chemo-immunotherapy resistance in lung adenocarcinoma by modulating the AKT signaling pathway.
Ruan J and 3 others. Funct Integr Genomics, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. SLC2A1 promotes chemo-immunotherapy resistance in lung adenocarcinoma by modulating the AKT signaling pathway. Papers, record 42955441. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42955441
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SLC2A1 promotes chemo-immunotherapy resistance in lung adenocarcinoma by modulating the AKT signaling pathway.
- Journal
- Funct Integr Genomics
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-11-05
Source PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma of Lung | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Proto-Oncogene Proteins c-akt | Major topic |
| Lung Neoplasms | Major topic |
| Humans | |
| Signal Transduction | |
| Cisplatin | |
| Immunotherapy | |
| Cell Line, Tumor | |
| Gene Expression Regulation, Neoplastic | |
| B7-H1 Antigen |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| JSKJ-KTQN-2024-03 | youth research project funded by the Jinshan District Health Commission and Science and Technology Commission | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36,358,765 | Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36358765 | PubMed |
| 2 | 40,849,659 | Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40849659 | PubMed |
| 3 | 36,810,079 | Lung cancer immunotherapy: progress, pitfalls, and promises. | Mol Cancer | 2023 | https://conductscience.org/library/papers/36810079 | PubMed |
| 4 | 32,042,191 | Regenerative lineages and immune-mediated pruning in lung cancer metastasis. | Nat Med | 2020 | https://conductscience.org/library/papers/32042191 | PubMed |
| 5 | 39,614,261 | AKT kinases as therapeutic targets. | J Exp Clin Cancer Res | 2024 | https://conductscience.org/library/papers/39614261 | PubMed |
| 6 | 33,433,946 | Cancer Statistics, 2021. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33433946 | PubMed |
| 7 | 40,740,483 | PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40740483 | PubMed |
| 8 | 36,313,041 | Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer. | J Cancer | 2022 | https://conductscience.org/library/papers/36313041 | PubMed |
| 9 | 38,215,748 | Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. | Cancer Cell | 2024 | https://conductscience.org/library/papers/38215748 | PubMed |
| 10 | 40,739,089 | Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/40739089 | PubMed |
1 to 10 of 28
See all 28 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42955441
GET https://conductscience.org/api/papers/v1/42955441/references?page=2